108 related articles for article (PubMed ID: 1284385)
1. [The diagnostic value of erythrocyte polyamines (EPA) in prostatic adenocarcinoma (PA): apropos of 100 patients].
Cipolla B; Guille F; Quemener V; Lévêque JM; Moulinoux JP; Lobel B
Prog Urol; 1992 Feb; 2(1):50-7. PubMed ID: 1284385
[TBL] [Abstract][Full Text] [Related]
2. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
[TBL] [Abstract][Full Text] [Related]
3. Erythrocyte polyamine levels in human prostatic carcinoma.
Cipolla B; Moulinoux JP; Quemener V; Havouis R; Martin LA; Guille F; Lobel B
J Urol; 1990 Nov; 144(5):1164-6. PubMed ID: 1700142
[TBL] [Abstract][Full Text] [Related]
4. [Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports].
Bordes M; Brunet-Lecomte P; Dusserre P; Dusserre-Guion L; Michiels-Marzais D; Morlevat F; Peny J; Roignot P; Colas JM; Ferry N
Ann Urol (Paris); 1989; 23(4):295-300. PubMed ID: 2480077
[TBL] [Abstract][Full Text] [Related]
5. Determination of erythrocyte polyamines as a predictive method in tumour diagnosis. An animal study with chemically induced tumours.
Quemener V; Havouis R; Khan NA; Martin C; Bouet F; Moulinoux JP
Anticancer Res; 1995; 15(6B):2517-22. PubMed ID: 8669816
[TBL] [Abstract][Full Text] [Related]
6. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte polyamines and prognosis in colorectal cancer patients.
Linsalata M; Leo S; Guerra V; Di Leo A
Anticancer Res; 2000; 20(3B):2113-7. PubMed ID: 10928162
[TBL] [Abstract][Full Text] [Related]
8. Polyamines and prostatic carcinoma: clinical and therapeutic implications.
Cipolla B; Guillé F; Moulinoux JP; Quemener V; Staerman F; Corbel L; Lobel B
Eur Urol; 1993; 24(1):124-31. PubMed ID: 7689970
[TBL] [Abstract][Full Text] [Related]
9. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
[No Abstract] [Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
[TBL] [Abstract][Full Text] [Related]
12. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
13. [Prostate-specific antigen as a prostatic tumor marker. Analysis of results in 206 patients].
Rodríguez Duarte C
Arch Esp Urol; 1991; 44(6):697-700. PubMed ID: 1722962
[TBL] [Abstract][Full Text] [Related]
14. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
Rodríguez Duarte C; Aguillón J; Rodríguez H
Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
[TBL] [Abstract][Full Text] [Related]
15. [TPS in prostate cancer].
Rodríguez-Rubio FI; Monreal I; Robles JE; Martín-Marquina A; Abad JI; Rosell D; Zudaire JJ; Berián JM
Actas Urol Esp; 1995 Feb; 19(2):131-3. PubMed ID: 7539573
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma.
Alivizatos G; Dimopoulos A; Mitropoulos D; Alevizou K; Bougas D; Pantazopoulos D
Arch Esp Urol; 1992 Apr; 45(3):269-72. PubMed ID: 1384439
[TBL] [Abstract][Full Text] [Related]
17. Determination of putrescine, spermine and spermidine in human tissues of prostate and kidney.
Dunzendorfer U; Russell DH
Arzneimittelforschung; 1980; 30(10):1801-4. PubMed ID: 6159903
[TBL] [Abstract][Full Text] [Related]
18. Polyamines in human breast cancer and its relations to classical prognostic features: clinical implications.
Leveque J; Bansard JY; Watier E; Catros-Quemener V; Havouis R; Moulinoux JP; Grall JY; Seiler N
Anticancer Res; 1999; 19(3B):2275-9. PubMed ID: 10472343
[TBL] [Abstract][Full Text] [Related]
19. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
20. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
